Hospital Sungai Buloh Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01091701
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hospital Sungai Buloh | Hospital Sungai Buloh Consultant Physician, Department of Medicine, Jalan Hospital, 47000 Sungai Buloh, Selangor | Sungai Buloh Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

favipiravir (1 trial)

inactivated SARS-Cov-2 vaccine (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3